Navigation Links
Alexza Reports 2008 Year-End Financial Results and Updates Clinical Pipeline Status
Date:3/10/2009

y has no direct ownership in Allegro, it reduces its net loss by the losses incurred by Allegro. "Loss attributed to noncontrolling interest in Symphony Allegro, Inc." reduced net loss for the quarter and year ended December 31, 2008 by $2.9 million and $18.6 million, and reduced net loss by $3.1 million and $10.8 million in the comparable periods in 2007.

Product Candidates Development Update

  • AZ-004 (Staccato loxapine). Alexza is developing AZ-004 for the acute treatment of agitation in patients with schizophrenia or bipolar disorder. AZ-004 is currently in Phase 3 clinical testing and the Company projects an NDA filing in early 2010.

In December 2008, the Company announced positive results from the second of its two Phase 3 clinical trials of AZ-004. This trial enrolled 314 acutely-agitated patients with bipolar I disorder at 17 U.S. clinical centers. The trial was designed as an in-clinic, multi-center, randomized, double-blind, placebo-controlled study, and tested AZ-004 at two dose levels, 5 mg and 10 mg. Patients were eligible to receive up to 3 doses of study drug in a 24-hour period, depending on their clinical status. Only one dose of study drug was allowed during the first 2 hours of the study period. Patients eligible for the study included those who were admitted through an emergency department and those who were already in-patients in a hospital setting, as long as they had acute agitation at the time of patient randomization. This study was the first AZ-004 study enrolling bipolar disorder patients. The primary endpoint for the study was a reduction of agitation, measured as the change from baseline in the PANSS, or Positive and Negative Symptom Scale, Excited Component Score, also known as the PEC score, measured at 2 hours after the first dose. The key secondary endpoint was the Clinical Global Impression-Improvement, or CGI-I, score,
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine news :

1. Alexzas Corporate Presentation to be Webcast at the Cowen & Company 29th Annual Health Care Conference
2. Alexza to Announce 2008 Financial Results and Update Its Clinical Pipeline on Tuesday, March 10, 2009
3. Alexza Pharmaceuticals Promotes Peter D. Noymer, PhD to Vice President, Product R&D
4. Alexza Pharmaceuticals Announces Upcoming Conference Participation and Webcasts
5. Alexza Reports 2008 Third Quarter Financial Results and Updates Development of Product Candidates
6. Alexza to Announce 2008 Third Quarter Financial Results and Update Its Clinical Pipeline on Thursday, November 6, 2008
7. Anthony Clarke, PhD Joins Alexza Pharmaceuticals as Vice President, International Development Operations
8. Jeffrey S. Williams Rejoins Alexza Pharmaceuticals as President, Alexza Singapore Pte. Ltd.
9. Carlos A. Parra Joins Alexza Pharmaceuticals as Vice President, Quality
10. Alexzas Corporate Presentation to be Webcast at the Seventh Annual JMP Securities Research Conference and the 2008 Citi Investment Research Global Healthcare Conference
11. Alexza to Webcast Investor and Analyst Day Presentations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2014)... of California, San Diego School of Medicine report that ... a recent major loss are more likely to be ... study is published in this month,s issue of the ... compassionate behaviors are associated with better health and well-being ... ways to improve the outcomes of individuals whose deficits ...
(Date:4/17/2014)... In a review published in the April issue ... of The Feinstein Institute for Medical Research, says it,s ... community,s approach to treating sepsis, which kills ... , Sepsis occurs when molecules released into the bloodstream ... the body. Inflammation is necessary for maintaining good health ...
(Date:4/17/2014)... Northwestern University synthetic biology team has created a ... programmable therapeutics that could travel the body and ... , Engineering cell-based, biological devices that monitor and ... clinical synthetic biology. However, no existing technology enabled ... patient,s physiological state and respond in a customized ...
(Date:4/17/2014)... Doctors who treat patients with a severe ... face an agonizing treatment decision. , The drug ... help relieve shortness of breath. But some patients ... cause potentially fatal complications following transplantation. , "It,s ... medical director of Loyola University Medical Center,s LAM ...
(Date:4/17/2014)... NEW YORK, NY (April 16, 2014) The cause ... but a new study proposes that neurons may be ... own immune system, similar to the way autoimmune diseases ... attack the body,s cells. The study was published April ... is a new, and likely controversial, idea in Parkinson,s ...
Breaking Medicine News(10 mins):Health News:The ilk of human kindness 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2Health News:Building 'smart' cell-based therapies 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:Is Parkinson's an autoimmune disease? 2
... , WASHINGTON , Jan. 15 ... with 22 national organizations, attended the first consortium meeting ... initiative to improve lupus diagnosis, treatment, and management among ... Rheumatology offices in Atlanta, Georgia from January ...
... FRANCISCO , Jan. 15 A Good Idea , a ... San Francisco , plans to give $100,000 to Haiti ... Community Giving contest sponsored by JPMorgan Chase & Co. , "While ... Bay Area, we feel that it is of the utmost importance to contribute ...
... , SANTA BARBARA, Calif. , Jan. 15 ... connecting essential micronutrients, especially vitamin A, with infants and children ... a disaster relief agency, Vitamin Angels has responded to ... Haiti , by shipping over 1 million children,s multivitamins. After ...
... , PHOENIX , Jan. 15 ... rice bran (SRB) nutrient research and technology, today announced a 17% ... to improve the company,s cost structure. The reduction, which is anticipated ... impact the workforce at Irgovel, NutraCea,s Brazilian subsidiary. , W. ...
... , OCEANSIDE, Calif. , Jan. 15 ... organizations that work with teens are tirelessly launching grassroots efforts to ... In many cities, the efforts are led by teens themselves. , ... cannot change the world.  But the people who see it can ...
... , Jan. 15 The March of Dimes has ... mothers and babies in Haiti imperiled by the devastating ... concerned about the thousands of pregnant women and moms caring for ... Dr. Jennifer L. Howse , president of the March of ...
Cached Medicine News:Health News:Lupus Foundation of America Collaborates with Federal Agencies and the U.S. Surgeon General's Office to Expand Medical Education on Lupus 2Health News:Lupus Foundation of America Collaborates with Federal Agencies and the U.S. Surgeon General's Office to Expand Medical Education on Lupus 3Health News:San Francisco Charity A GOOD IDEA to Give $100,000 to Haiti Victims Upon Winning Nationwide Charity Program 2Health News:Vitamin Angels Responds to Haiti Disaster 2Health News:NutraCea Announces Reduction in Workforce in U.S. Operations 2Health News:Movie Turns Into a Growing Movement to Reach Hurting Teens. 2Health News:Movie Turns Into a Growing Movement to Reach Hurting Teens. 3Health News:Movie Turns Into a Growing Movement to Reach Hurting Teens. 4Health News:Movie Turns Into a Growing Movement to Reach Hurting Teens. 5Health News:March of Dimes Supports Urgent Needs of Mothers and Babies in Haiti Earthquake 2
(Date:1/14/2014)... , Jan. 14, 2014 HeartWare International, ... innovator of less invasive, miniaturized circulatory support technologies that ... announced that it expects revenues for the fourth quarter ... full-year 2013 revenues to approximately $208 million. ...
(Date:1/14/2014)... North America,s leading business partnering event ... 30 th edition of its annual conference at the ... 21-24. (Logo: http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ) ... specialty chemical companies will take part in the conference, which ...
(Date:1/14/2014)... , Jan. 14, 2014 Dynamic Healthcare Services, Inc. ("DHS"), ... that it acquired Progressive Home Medical Equipment, Inc. ("Progressive") of ... The terms of the acquisition were not disclosed. ... company providing a wide range of sleep, mobility, and respiratory ...
Breaking Medicine Technology:HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3
... REMICADE Therapy is More Likely to Induce Steroid-Free Remission ... ... Data presented for the first time,from the Phase 3b Study ... may provide new insights into,the approach to care of patients with ...
... More than 60 percent of moderate to severe ... achieved endoscopic remission at Week 10,in data from ... College,of Gastroenterology (ACG) Annual Scientific Meeting, ORLANDO, ... from a,large, prospective study investigating endoscopic improvement in ...
Cached Medicine Technology:New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 2New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 3New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 4New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 5New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 6New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 7New Findings Show Efficacy of REMICADE(R) Compared With Azathioprine in Treatment of Crohn's Disease According to First-of-its Kind Study 8CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 2CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 3CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 4CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 5CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 6CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients 7
... grafting or creation of a vascular access, ... is of the utmost importance in many ... for those seeking a high-precision tunneling instrument. ... risk of twisting or kinking for more ...
... Stretch Vascular Grafts have met the ... procedures. Recognized for exceptional performance and ... of renowned surgeons worldwide. These grafts ... the spread of infection, and ensure ...
... Today's evolving techniques for vascular surgery, ... require that new, specialized types of graft ... strong, inert and biocompatible, but also available ... vascular access. GORE-TEX Vascular Graft has long ...
... INTERING Vascular Graft, the newest vascular graft ... a leader in vascular surgical products for ... by reducing kinking and compression problems ... new graft provides all of the benefits ...
Medicine Products: